Stockscreener 앱 받기
1.76
4.86%
-0.09
전일 마감가:
$1.85
열려 있는:
$1.92
하루 거래량:
26,978
Relative Volume:
0.85
시가총액:
$3.77M
수익:
$407.80K
순이익/손실:
$-9.90M
주가수익비율:
-0.1414
EPS:
-12.4498
순현금흐름:
$-9.00M
1주 성능:
-7.37%
1개월 성능:
-21.43%
6개월 성능:
-42.86%
1년 성능:
-83.70%
1일 변동 폭
$1.75
$1.92
1주일 범위
$1.75
$2.02
52주 변동 폭
$1.75
$12.30
캔 파이트 바이오파마 Stock (CANF) Company Profile
명칭
Can-Fite Biopharma Ltd ADR
전화
972 3 924 1114
주소
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
1.76 | 3.77M | 407.80K | -9.90M | -9.00M | -12.45 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
캔 파이트 바이오파마 Stock (CANF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-13 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-10-19 | 재개 | ROTH Capital | Buy |
| 2016-08-29 | 재개 | Rodman & Renshaw | Buy |
| 2015-11-30 | 재확인 | H.C. Wainwright | Buy |
| 2015-03-31 | 재확인 | H.C. Wainwright | Buy |
| 2015-03-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-29 | 재확인 | ROTH Capital | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
모두보기
캔 파이트 바이오파마 주식(CANF)의 최신 뉴스
With financing closed, Scinai (SCNI) estimates runway to late 2027, subject to sales, collections and execution. - Stock Titan
Each depositary share represents 10,000 ordinary shares at RedHill Biopharma (RDHL). - Stock Titan
Nasdaq gives RedHill Biopharma (NASDAQ: RDHL) more time to clear its $1 bid-price hurdle - Stock Titan
If all warrants are exercised for cash, Can-Fite (CANF) could receive $8.31M as it registers shares for resale. - Stock Titan
Warrants on 7.6M CANF shares highlight dilution risk - Stock Titan
CANFCan-Fite Biopharma Ltd ADR Short Interest - Finviz
Repriced deal gives Can-Fite (CANF) $4M cash and 3.18M new ADS warrants - Stock Titan
CANF 6-K & SEC Filings - Yahoo Finance Australia
Which stocks are gapping on Wednesday? - ChartMill
Discover the top movers in Wednesday's pre-market session. - ChartMill
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - globenewswire.com
Can-Fite BioPharma (CANF) halves warrant price in cash-for-warrants deal - Stock Titan
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - markets.businessinsider.com
Can-Fite (CANF) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: The Stock Records a 0.60% Decrease on the DayFinal Results - careplusvn.com
Can-Fite (CANF) Quarterly Figures: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: The Stock Records a 0.60% Decrease on the DayShort-Term Outlook - dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionALMA Signal - careplusvn.com
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionETF Liquidity - dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionDouble Bottom - siam.in
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionZero Lag EMA - www.dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionFear Greed Index - dars.gov.et
Can-Fite (CANF): Slides 0.60% to $3.33 in the Latest Reading; Price Setup: the Current Price Sits Inside the Supplied Technical Range for the Current SessionMACD Signal Stocks - www.dars.gov.et
Can-Fite (CANF) Range: Loses 0.29% to Close at $3.44 for the Current Session; Next Test: $3.27 and $3.61 Define the Nearby Reference Levels in the Current UpdateGap and Reverse - careplusvn.com
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates - Sahm
Baidu, Inc. (BIDU) CEO logs 852,904 restricted share conversions and major Class B stake - Stock Titan
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - GlobeNewswire Inc.
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Hesai Group (NYSE: HSAI) enacts 1-for-8 share subdivision and updates ADS ratio - Stock Titan
Why is Can-Fite BioPharma stock climbing today? - Investing.com
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients - Sahm
H.C. Wainwright raises Can-Fite BioPharma price target to $8 on trial data - Investing.com
On Wednesday, there are stocks with unusual volume. Let's take a look. - ChartMill
Wednesday's session: gap up and gap down stocks - ChartMill
Can Fite Biopharma stock surges 65% on pancreatic cancer data By Investing.com - Investing.com Nigeria
Can Fite Biopharma stock surges 65% on pancreatic cancer data - Investing.com
What's going on in today's pre-market session - ChartMill
Can-Fite BioPharma Ltd. Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
Friday's after hours session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Can Fite Biopharma stock jumps on Japan patent for obesity drug - Investing.com South Africa
Can-Fite BioPharma (NYSEAMERICAN:CANF) jumps after Japan patent update - TechStock²
Top movers in Friday's pre-market session - ChartMill
Can-Fite BioPharma Ltd. Sponsored ADR Actuals & Estimates (AMEX:CANF) - TradingView
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - Sahm
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com South Africa
Form 6K Can-Fite BioPharma Ltd. For: 22 June By Investing.com - Investing.com Canada
RedHill closes $6M financing, with up to $13.4M more possible - Stock Titan
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - Sahm
CANF Stock Price, Quote & Chart - ChartMill
캔 파이트 바이오파마 (CANF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.22%
자본화:
|
볼륨(24시간):